Grifols announced the launch of the SPIRIT (Study of Plasma-derived factor VIII/VWF in Immune toleRance Induction Therapy) registry for patients with hemophilia A at the National Hemophilia Foundation’s 65th Annual Meeting in Anaheim, CA, in October 3-5, 2013.
In January 2014, the company announced a name change from the SPIRIT registry to PRISM (Prospective Observational Study of Plasma-derived FVIII/VWF in Immune Tolerance Induction). PRISM will enroll U.S. patients with hemophilia A and inhibitors being treated with ALPHANATE®, Grifols’ plasma-derived factor VIII/von Willebrand factor product.
Source: Grifols
